• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Studies on the optimal combination therapy with radiation and new anticancer agents

Research Project

Project/Area Number 09470200
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypeSingle-year Grants
Section一般
Research Field Radiation science
Research InstitutionKYOTO UNIVERSITY

Principal Investigator

SHIBAMOTO Yuta  KYOTO UNIVERSITY,Institute for Frontier Medical Sciences Associate Professor, 再生医科学研究所, 助教授 (20144719)

Co-Investigator(Kenkyū-buntansha) 高橋 正治  京都大学, 胸部疾患研究所, 教授 (00026931)
Project Period (FY) 1997 – 1998
Project Status Completed (Fiscal Year 1998)
Budget Amount *help
¥3,900,000 (Direct Cost: ¥3,900,000)
Fiscal Year 1998: ¥1,700,000 (Direct Cost: ¥1,700,000)
Fiscal Year 1997: ¥2,200,000 (Direct Cost: ¥2,200,000)
KeywordsRadiotherapy / Chemotherapy / 5-Fluorouracil / Emitefur / Prodrug / 放射線治療 / 併用療法 / エミテフ-ル
Research Abstract

We investigated the combined effect of radiation and emitefur, a newly developed anticancer agent consisting of a masked form of 5-fluorouracil (5-FU) and a potent inhibitor of 5-FU degradation, in murine tumors. Emitefur at doses of 12.5 and 25 mg/kg was evaluated either alone or in combination with single (15 Gy), 5-fraction (4 Gy each) or 10-fraction (2.8 Gy each) irradiation using a tumor growth delay assay for SCCVII tumors and in combination with 4-fraction (5 Gy each) irradiation using an in vivo-in vitro assay for EMT6 tumors. The antitumor and radiation-enhancing effects of 12.5 mg/kg emitefur were not significant in any except the 10-fraction experiment. On the other hand, multiple doses of 25 mg/kg emitefur given either alone or in combination with radiation produced marked effects. The increase in growth delay afforded by this combination was at least additive. The effect of 4 fractions of 5 Gy with 25 mg/kg emitefur in EMT6 tumors was lower than that of 4 fractions of 7.5 … More Gy, but the effect of 5 fractions of 4 Gy with this dose of emitefur in SCCVII tumors was similar to the effect of 5 fractions of 6 Gy, and the effect of 10 fractions of 2.8 Gy with 25mg/kg emitefur was much higher than that of 10 fractions of 4.2 Gy. Emitefur given either alone or in combination with radiation appeared to have a significant antitumor effect even at clinically relevant dose levels, although a threshold dose exists between 12.5 and 25 mg/kg. Further clinical studies of this compound are warranted.
We also investigated the radiation chemical reactivity and biological effects of an antitumor prodrug of 5-FU, OFU001 [1 -(2'-oxopropyl)-5-fluorouracil]. Release of 5-FU from OFU001 dissolved in phosphate buffer following aerobic or hypoxic irradiation was measured by high-performance liquid chromatography. To investigate in vitro antitumor effect, the compound dissolved in culture medium was irradiated under both aerobic and hypoxic conditions and SCCVII cells were cultured with the medium for 1 to 6 h. The compound released 5-FU at a G-value of 1.8 following hypoxic irradiation but at 0.1 following aerobic irradiation. OFU001 irradiated at 15-30 Gy under hypoxic conditions had cytotoxic effect against SCCVII cells, whereas the compound irradiated under aerobic conditions showed little cytotoxicity. Our study suggested the possibility of developing new radiation-activating antitumor prodrugs using this idea.
Furthermore, weanalyzed the clinical results of combined radiotherapy and chemotherapy for esophageal and lung cancers. The studies had been performed at University Hospital, Kragujevac, Yugoslavia The analyses showed very promising results which appeared to be superior to those obtained by radiotherapy alone. Less

Report

(3 results)
  • 1998 Annual Research Report   Final Research Report Summary
  • 1997 Annual Research Report
  • Research Products

    (17 results)

All Other

All Publications (17 results)

  • [Publications] Branislav Jeremic: "Carboplatin, etoposide and accelerated hyperfractionated radiotherapy for elderly patients with limited small cell lung carcinoma" Cancer. 82・5. 836-841 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Branislav Jeremic: "Accelaerated hyperfractionated radiation therapy and concurrent 5-fluorouracil/cisplatin chemotherapy for locoregional squamous cell carcinoma of the thoracic esophagus" International Journal of Radiation Oncology Biology Physics. 40・5. 1061-1066 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Branislav Jeremic: "Concurrent radiochemotherapy for patients with stageIII non-small-cell lung cancer(NSCLC) : long-term results of a phase II study" International Journal of Radiation Oncology Biology Physics. 42・5. 1091-1096 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Yuta Shibamoto: "Systemic chemotherapy with vincristine, cyclophosphomide, doxorubicin and prednisolone following radiotherapy for primary central nervous system lymphoma. Aphase II study." Journal of Neuro-Oncology. 印刷中 (1999)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Yuta Shibamoto: "A phase I/II study of a hypoxic cell radiosensitizer KU-2285 in combination with intraoperative radiotherapy" British Journal of Cancer. 76・11. 1474-1479 (1997)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Shibamoto Y,Ohshio G,Hosotani R,Nishimura Y,Manabe T,Imamura M,Abe M.: "A phase I/II study of a hypoxic cell radiosensitizer KU-2285 in combination with intraoperative radiotherapy." Br J Cancer. 76. 1474-1479 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Jeremic B,Shibamoto Y,Acimovic L,Milisavljevic S.: "Carboplatin, etoposide and accelerated hyperfractionated radiotherapy for elderly patients with limited small cell lung carcinoma.A Phase II study." Cancer. 82. 836-841 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Jeremic B,Shibamoto Y,Acimovic L,Matovic Z,Milicic B,Milisavljevic S,Nikolic N.: "Accelerated hyperfractionated radiation therapy and concurrent 5-FU/CDDP chemotherapy for locoregional squamous cell carcinoma of the thoracic esophagus. A Phase II study." Int J Radiat Oncol Biol.Phys. 40. 1061-1066 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Jeremic B,Shibamoto Y,Milicic B,nikolic N,Dagovic A,Milisavljevic S.: "Concurrent radiochemotherapy for patients with Stage III non-small-cell lung cancer(NSCLC) : long-term results of a Phase II study." Int J Rdiat Oncol Biol Phys. 42. 1091-1096 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Shibamoto Y,Sasaki K,Oya N,Hiraoka M.: "Systemic chemotherapy with vincristine, cyclophoshpamide, doxorubicin and prednisolone following radiotherapy for primary central nervous system lymphoma : a Phase II study." J Neuro-Oncol. (in press). (1999)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Bronislav Jeremic: "Carboplatin,etoposide and accelerated hyperfractionated radiotherapy for elderly patients with limited small-cell lung carcinoma." Cancer. 82・5. 836-841 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] Branislav Jeremic: "Accelerated hyperfractionated radiation therapy and concurrent 5-fluoreuracil/cisplatin chemothrapy for locoragincal squmuas cell carcinoma of the thoracic esoplugus" International Journal of Radiation Oncology Biology Physics. 40・5. 1061-1066 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] Branislav Jeremic: "Concurrent radiochimetherapy for patients with Stage III non-small-cell lung cancer (NSCLC):long-term results of a phase II study" International Journal of Radiation Oncology Biology Physics. 42・5. 1091-1096 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] Yuta Shibamoto: "Systemic chemotherapy with vincristine cyclophosphanide,dexorubicin and prednisolone following radiotherapy for primary central nerrass system lympherma" Journal of Neuro Oncology. (印刷中). (1999)

    • Related Report
      1998 Annual Research Report
  • [Publications] Y.Shibamoto 他6名: "A phase I/II study of a hypoxic cell radiosensitizer KU-2285 in combination with intraoperative radiotherapy" British Journal of Cancer. 76・11. 1474-1479 (1997)

    • Related Report
      1997 Annual Research Report
  • [Publications] B.Jeremic, Y.Shibamoto 他4名: "Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck : a prospective randomized trial" Radiotherapy and Oncology. 43・1. 29-37 (1997)

    • Related Report
      1997 Annual Research Report
  • [Publications] B.Jeremic, Y.Shibamoto 他2名: "Carboplatin,etoposide and accelerated hyperfractionated radiotherapy for elderly patients with limited small cell lung cancer : aphase II study" Cancer. 82・5. 836-841 (1998)

    • Related Report
      1997 Annual Research Report

URL: 

Published: 1997-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi